2nd Annual Perspectives in Breast Cancer Care

CME Activities

• PET Imaging and Beyond
  Medscape Education Radiology, December 2022
  How is your imaging practice informing treatment and improving outcomes for patients with breast cancer?
  2.50 CME

  2.50 ABIM MOC

  2.50 CE
• Breast Cancer Risk Assessment and Screening
  Medscape Education Radiology, November 2022
  How are you identifying patients at increased risk for breast cancer and how are you mitigating that risk?
  2.50 CME

  2.50 ABIM MOC

  2.50 CE

• A Clinical Case Symposium: New Therapies in Early Breast Cancer
  Medscape Education Oncology, December 2022
  Join this discussion to hear our experts discuss the incorporation of targeted agents into the treatment of early breast cancer.
  1.25 CME

  1.25 ABIM MOC
• Special Topics in HR-Positive Breast Cancer
  Medscape Education Oncology, November 2022
  Did you know that approximately 65% to 70% of all breast cancers express hormone receptors in the absence of HER2 amplification?
  1.50 CME

  1.50 ABIM MOC

  1.50 CE

  1.50 CE
• Early Disease Considerations in HR-Positive Breast Cancer
  Medscape Education Oncology, November 2022
  Did you know that about 20% of HR-positive HER2-negative EBCs are primary endocrine therapy-resistant and have high risk of early recurrence?
  1.75 CME

  1.75 ABIM MOC

  1.75 CE

  1.75 CE
• Metastatic Disease Considerations in HR-Positive Breast Cancer
  Medscape Education, November 2022
  Did you know that ribociclib and abemaciclib are 4- and 5-times more selective toward CDK4 over CDK6?
  1.50 CME

  1.50 ABIM MOC

  1.50 CE

  1.50 CE

• A Clinical Case Symposium: Targeted Therapies in HER2-Positive Breast Cancer
  Medscape Education Oncology, December 2022
  Join this discussion to hear our experts discuss the management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer across multiple lines of therapy.
  1.25 CME

  1.25 ABIM MOC
• Early Disease Considerations in HER2-Positive Breast Cancer
  Medscape Education Oncology, December 2022
  New treatments can improve the survival outcomes for women with HER2-positive breast cancer. These presentations highlight the management of early HER2-positive breast cancer.
  1.50 CME

  1.50 ABIM MOC

  1.50 CE

  1.50 CE
• Metastatic Disease Considerations in HER2-Positive Breast Cancer
  Medscape Education Oncology, December 2022
  Are you up to date on the latest data regarding metastatic HER2-positive breast cancer?
  1.25 CME

  1.25 ABIM MOC

  1.25 CE

  1.25 CE
• Special Topics in HER2-Positive Breast Cancer
  Medscape Education Oncology, December 2022
  Top breast cancer experts cover the latest data on brain metastases in breast cancer, HER2-low breast cancer and HER2 testing.
  1.50 CME

  1.50 ABIM MOC

  1.50 CE

  1.50 CE

• Metastatic Disease Considerations in Triple Negative Breast Cancer
  Medscape Education Oncology, December 2022
  Are you up to date on optimal strategies for managing metastatic triple-negative breast cancer (mTNBC)?
  2.00 CME

  2.00 ABIM MOC

  2.00 CE

  2.00 CE
• Early Disease Considerations in Triple Negative Breast Cancer
  Medscape Education Oncology, December 2022
  Are you looking to get up to speed about emerging research on ctDNA, systemic therapy, and managing toxicity in early-stage triple negative breast cancer? Learn more here.
  1.00 CME

  1.00 ABIM MOC

  1.00 CE

  1.00 CE